失代偿性心力衰竭早期和晚期达帕格列净用药比较

The British journal of cardiology Pub Date : 2024-03-07 eCollection Date: 2024-01-01 DOI:10.5837/bjc.2024.010
Takahiro Tokuda, Yoriyasu Suzuki, Ai Kagase, Hiroaki Matsuda, Akira Murata, Tatsuya Ito
{"title":"失代偿性心力衰竭早期和晚期达帕格列净用药比较","authors":"Takahiro Tokuda, Yoriyasu Suzuki, Ai Kagase, Hiroaki Matsuda, Akira Murata, Tatsuya Ito","doi":"10.5837/bjc.2024.010","DOIUrl":null,"url":null,"abstract":"<p><p>Sodium-glucose cotransporter 2 inhibitors have demonstrated positive effects in heart failure (HF) patients. However, the effects of dapagliflozin in patients with decompensated HF remain unclear. This study aimed to compare the efficacy and safety of early and late dapagliflozin administration for decompensated HF. Data regarding dapagliflozin administration from 70 patients diagnosed with HF between December 2020 and November 2021 at a Japanese heart centre were analysed retrospectively. Propensity score matching was performed to compare the clinical outcomes of early and late dapagliflozin administration for decompensated HF. The primary end point was HF admission one year after dapagliflozin administration. The secondary end points were evaluated based on 24-hour urine volume, cardiac death, changes in ejection fraction (EF), blood pressure, glomerular filtration rate (GFR), haemoglobin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and side effects within one year of treatment. Fifteen matched pairs of patients were analysed. Admission rate within one year was significantly lower in the early administration group than in the late administration group (0 <i>vs.</i> 20%, p=0.03). Secondary end points were not significantly different between the two groups. In conclusion, early dapagliflozin administration significantly reduced HF admission within one year of treatment, although no differences were observed in 24-hour urine volume, cardiac death, EF, GFR, haemoglobin and NT-proBNP levels, and side effects.</p>","PeriodicalId":74959,"journal":{"name":"The British journal of cardiology","volume":"31 1","pages":"010"},"PeriodicalIF":0.0000,"publicationDate":"2024-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421070/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison between early and late dapagliflozin administration for decompensated heart failure.\",\"authors\":\"Takahiro Tokuda, Yoriyasu Suzuki, Ai Kagase, Hiroaki Matsuda, Akira Murata, Tatsuya Ito\",\"doi\":\"10.5837/bjc.2024.010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Sodium-glucose cotransporter 2 inhibitors have demonstrated positive effects in heart failure (HF) patients. However, the effects of dapagliflozin in patients with decompensated HF remain unclear. This study aimed to compare the efficacy and safety of early and late dapagliflozin administration for decompensated HF. Data regarding dapagliflozin administration from 70 patients diagnosed with HF between December 2020 and November 2021 at a Japanese heart centre were analysed retrospectively. Propensity score matching was performed to compare the clinical outcomes of early and late dapagliflozin administration for decompensated HF. The primary end point was HF admission one year after dapagliflozin administration. The secondary end points were evaluated based on 24-hour urine volume, cardiac death, changes in ejection fraction (EF), blood pressure, glomerular filtration rate (GFR), haemoglobin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and side effects within one year of treatment. Fifteen matched pairs of patients were analysed. Admission rate within one year was significantly lower in the early administration group than in the late administration group (0 <i>vs.</i> 20%, p=0.03). Secondary end points were not significantly different between the two groups. In conclusion, early dapagliflozin administration significantly reduced HF admission within one year of treatment, although no differences were observed in 24-hour urine volume, cardiac death, EF, GFR, haemoglobin and NT-proBNP levels, and side effects.</p>\",\"PeriodicalId\":74959,\"journal\":{\"name\":\"The British journal of cardiology\",\"volume\":\"31 1\",\"pages\":\"010\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11421070/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The British journal of cardiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5837/bjc.2024.010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The British journal of cardiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5837/bjc.2024.010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

钠-葡萄糖共转运体 2 抑制剂对心力衰竭(HF)患者有积极作用。然而,达帕格列净对失代偿性心力衰竭患者的疗效仍不明确。本研究旨在比较早期和晚期服用达帕格列净治疗失代偿性心力衰竭的疗效和安全性。研究回顾性分析了一家日本心脏中心在 2020 年 12 月至 2021 年 11 月期间确诊的 70 例心房颤动患者的达帕格列净用药数据。对失代偿性心房颤动患者早期和晚期服用达帕格列净的临床结果进行了倾向评分匹配比较。主要终点是服用达帕格列净一年后的心房颤动入院情况。次要终点根据24小时尿量、心源性死亡、射血分数(EF)变化、血压、肾小球滤过率(GFR)、血红蛋白和N末端前B型钠尿肽(NT-proBNP)水平以及治疗一年内的副作用进行评估。对 15 对匹配的患者进行了分析。早期用药组一年内的入院率明显低于晚期用药组(0 对 20%,P=0.03)。两组患者的次要终点无明显差异。总之,虽然在24小时尿量、心脏死亡、EF、GFR、血红蛋白和NT-proBNP水平以及副作用方面未观察到差异,但早期服用达帕格列净可显著降低治疗一年内的HF入院率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparison between early and late dapagliflozin administration for decompensated heart failure.

Sodium-glucose cotransporter 2 inhibitors have demonstrated positive effects in heart failure (HF) patients. However, the effects of dapagliflozin in patients with decompensated HF remain unclear. This study aimed to compare the efficacy and safety of early and late dapagliflozin administration for decompensated HF. Data regarding dapagliflozin administration from 70 patients diagnosed with HF between December 2020 and November 2021 at a Japanese heart centre were analysed retrospectively. Propensity score matching was performed to compare the clinical outcomes of early and late dapagliflozin administration for decompensated HF. The primary end point was HF admission one year after dapagliflozin administration. The secondary end points were evaluated based on 24-hour urine volume, cardiac death, changes in ejection fraction (EF), blood pressure, glomerular filtration rate (GFR), haemoglobin and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and side effects within one year of treatment. Fifteen matched pairs of patients were analysed. Admission rate within one year was significantly lower in the early administration group than in the late administration group (0 vs. 20%, p=0.03). Secondary end points were not significantly different between the two groups. In conclusion, early dapagliflozin administration significantly reduced HF admission within one year of treatment, although no differences were observed in 24-hour urine volume, cardiac death, EF, GFR, haemoglobin and NT-proBNP levels, and side effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信